Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Nathaniel Keller

Psychiatry Orlando, FL Medical Doctor

NPI 1144411844 CMS profile 323908

52 W Underwood St, Orlando, FL 32806

Open in the dashboard

General payments

$12,008

64 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Nathaniel Keller of Orlando, FL is reported in the CMS Open Payments database as having received $12,008 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $14 1
2020 General $81 6
2019 General $11,912 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathaniel Keller
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Nathaniel Keller were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Nathaniel Keller Psychiatry median Middle half National median
2019 $11,912 $184 $59–$605 $163
2020 $81 $119 $36–$372 $114
2021 $14 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Takeda Pharmaceuticals U.S.A., Inc. $11,115 12 payments
  2. Allergan Inc. $238 16 payments
  3. Bausch Health US, LLC $158 9 payments
  4. Lundbeck LLC $132 7 payments
  5. Sunovion Pharmaceuticals Inc. $89 5 payments
  6. Teva Pharmaceuticals USA, Inc. $81 4 payments
  7. Ironshore Pharmaceuticals Inc. $48 3 payments
  8. Janssen Pharmaceuticals, Inc $33 2 payments
  9. Brainsway USA Inc $24 1 payment
  10. Shire North American Group Inc $23 1 payment
  11. Other $67 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,968 6 payments
  2. Food and Beverage $1,035 57 payments
  3. Travel and Lodging $5 1 payment
Products named General payments · program years 2019–2021
  1. Trintellix Central Nervous System (CNS) $10,991 10 payments
  2. VRAYLAR $238 16 payments
  3. APLENZIN $148 8 payments
  4. REXULTI $132 7 payments
  5. TRINTELLIX Neuroscience $124 2 payments
  6. LATUDA $89 5 payments
  7. AUSTEDO $81 4 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $36 2 payments
  9. SPRAVATO $33 2 payments
  10. BrainsWay Deep TMS $24 1 payment
  11. Other $112 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,414

Median for Psychiatry: 574

Drug cost

$22,350

Median for Psychiatry: $27,624

Branded share of claims

14.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aripiprazole Generic 33 $4,956
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 26 $2,450
Bupropion Xl Bupropion Hcl Brand 114 $2,409
Sertraline Hcl Generic 188 $1,712
Clonazepam Generic 172 $1,437
Alprazolam Generic 237 $1,182
Duloxetine Hcl Generic 74 $1,016
Lamotrigine Generic 44 $898
Quetiapine Fumarate Generic 47 $897
Fluoxetine Hcl Generic 88 $830

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$61,071

Medicare's payments for the services billed

Medicare patients

260

Average age 68

Services billed

775

124 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 53%
Diabetes 45%
Chronic kidney disease 39%
Ischemic heart disease 38%
Alzheimer's or dementia 36%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record